Medesis Pharma S.A. (ALMDP.PA)
EUR 0.34
(-2.86%)
EUR 0.34
(-2.86%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 1.2 Million EUR | -9.83% |
| 2022 | 1.33 Million EUR | 3.64% |
| 2021 | 1.28 Million EUR | 586218.72% |
| 2020 | 219.00 EUR | -99.99% |
| 2019 | 1.78 Million EUR | 17.01% |
| 2018 | 1.52 Million EUR | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 Q2 | 1.2 Million EUR | -52.64% |
| 2023 FY | 1.2 Million EUR | -9.83% |
| 2023 Q4 | 1.2 Million EUR | -55.21% |
| 2023 Q3 | 2.67 Million EUR | 123.28% |
| 2023 Q1 | 2.53 Million EUR | 90.42% |
| 2022 Q4 | 1.33 Million EUR | 0.0% |
| 2022 Q3 | 1.33 Million EUR | 3.64% |
| 2022 FY | 1.33 Million EUR | 3.64% |
| 2022 Q2 | 1.28 Million EUR | 0.0% |
| 2022 Q1 | 1.28 Million EUR | 0.0% |
| 2021 Q3 | 1.28 Million EUR | 0.0% |
| 2021 Q2 | 1.28 Million EUR | 0.0% |
| 2021 Q1 | 1.28 Million EUR | 586218.72% |
| 2021 Q4 | 1.28 Million EUR | 0.0% |
| 2021 FY | 1.28 Million EUR | 586218.72% |
| 2020 Q2 | 2.07 Million EUR | 0.0% |
| 2020 FY | 219.00 EUR | -99.99% |
| 2020 Q4 | 219.00 EUR | -99.98% |
| 2020 Q3 | 1.28 Million EUR | -37.94% |
| 2019 FY | 1.78 Million EUR | 17.01% |
| 2018 FY | 1.52 Million EUR | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| ABIONYX Pharma SA | 3.39 Million EUR | 64.602% |
| ABIVAX Société Anonyme | 55.46 Million EUR | 97.836% |
| Adocia SA | 13.08 Million EUR | 90.831% |
| Aelis Farma SA | 4.03 Million EUR | 70.282% |
| Biophytis S.A. | 8.27 Million EUR | 85.49% |
| Advicenne S.A. | 17.42 Million EUR | 93.113% |
| genOway Société anonyme | 7.23 Million EUR | 83.41% |
| IntegraGen SA | 1.12 Million EUR | -6.692% |
| Neovacs S.A. | 650 Thousand EUR | -84.615% |
| NFL Biosciences SA | 62.17 Thousand EUR | -1830.067% |
| Plant Advanced Technologies SA | 4.35 Million EUR | 72.455% |
| Quantum Genomics Société Anonyme | 2.71 Million EUR | 55.831% |
| Sensorion SA | 2.86 Million EUR | 58.17% |
| Theranexus Société Anonyme | 3.64 Million EUR | 67.06% |
| TME Pharma N.V. | 1.16 Million EUR | -2.916% |
| Valbiotis SA | 6.87 Million EUR | 82.553% |
| TheraVet SA | 1.15 Million EUR | -3.46% |
| Valerio Therapeutics Société anonyme | 8.99 Million EUR | 86.664% |
| argenx SE | 18.1 Million EUR | 93.372% |
| BioSenic S.A. | 28.16 Million EUR | 95.739% |
| Celyad Oncology SA | 902 Thousand EUR | -33.038% |
| DBV Technologies S.A. | 13.01 Million USD | 90.782% |
| Galapagos NV | 9.59 Million EUR | 87.495% |
| Genfit S.A. | 70.17 Million EUR | 98.29% |
| GeNeuro SA | 7.73 Million EUR | 84.492% |
| Hyloris Pharmaceuticals SA | 5.29 Million EUR | 77.333% |
| Innate Pharma S.A. | 39.89 Million EUR | 96.992% |
| Inventiva S.A. | 37.4 Million EUR | 96.792% |
| MaaT Pharma SA | 14.07 Million EUR | 91.474% |
| MedinCell S.A. | 58.96 Million EUR | 97.965% |
| Nanobiotix S.A. | 50.56 Million EUR | 97.627% |
| Onward Medical N.V. | 16.87 Million EUR | 92.888% |
| Oryzon Genomics S.A. | 13.68 Million EUR | 91.233% |
| OSE Immunotherapeutics SA | 45.8 Million EUR | 97.38% |
| Oxurion NV | 12.33 Million EUR | 90.271% |
| Pharming Group N.V. | 155.29 Million EUR | 99.227% |
| Poxel S.A. | 46.9 Million EUR | 97.441% |
| GenSight Biologics S.A. | 18.42 Million EUR | 93.488% |
| Transgene SA | 1.25 Million EUR | 4.535% |
| Financière de Tubize SA | 79.2 Million EUR | 98.485% |
| UCB SA | 3.03 Billion EUR | 99.961% |
| Valneva SE | 208.81 Million EUR | 99.425% |
| Vivoryon Therapeutics N.V. | 38 Thousand EUR | -3057.895% |